Business Context and Reporting Period
This Form 8-K Current Report was filed by Harvard Bioscience, Inc. on January 18, 2023. The report discloses a material corporate governance event regarding the departure of a senior executive officer.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on personnel changes and associated contractual agreements.
Material Changes
- Executive Departure: Michael Rossi resigned as Chief Financial Officer and Treasurer, effective December 31, 2022.
- Separation Agreement: A Separation Agreement and Release was executed on January 18, 2023.
- Transition Period: Mr. Rossi will remain an employee until May 10, 2023, to provide transition assistance.
- Compensation Terms: The Company will continue to pay Mr. Rossi's base salary and maintain his participation in employee benefit plans through the Separation Date, contingent upon his execution of a release of claims and adherence to post-employment obligations.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, financial outlook, or management commentary regarding future business performance. The primary contingency noted is the conditionality of Mr. Rossi's separation payments on his non-revocation of the release of claims.
Investor Verification Checklist
- Verify the appointment of a new Chief Financial Officer and Treasurer to replace Michael Rossi.
- Review the full text of the Separation Agreement (Exhibit 10.1) for specific details on severance amounts or non-compete clauses not summarized in the text.
- Monitor subsequent filings for any impact on the company's internal controls or financial reporting processes during the transition period.